메뉴 건너뛰기




Volumn 13, Issue 9, 2014, Pages 949-960

The challenge and promise of anti-epileptic therapy development in animal models

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; BIOLOGICAL MARKER; ETIRACETAM; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NEUROTRANSMITTER; TOPIRAMATE;

EID: 84906280998     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70076-6     Document Type: Note
Times cited : (94)

References (49)
  • 1
    • 79953705357 scopus 로고    scopus 로고
    • Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma
    • Löscher W, Schmidt D Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011, 52:657-678.
    • (2011) Epilepsia , vol.52 , pp. 657-678
    • Löscher, W.1    Schmidt, D.2
  • 2
    • 84857648355 scopus 로고    scopus 로고
    • Identification of new epilepsy treatments: issues in preclinical methodology
    • the American Epilepsy Society Basic Science Committee, The International League Against Epilepsy Working Group On Recommendations For Preclinical Epilepsy Drug DiscoveryThe International League Against Epilepsy Working Group On Recommendations For Preclinical Epilepsy Drug Discovery
    • Galanopoulou AS, Buckmaster PS, Staley KJ, et al. Identification of new epilepsy treatments: issues in preclinical methodology. Epilepsia 2012, 53:571-582. the American Epilepsy Society Basic Science Committee, The International League Against Epilepsy Working Group On Recommendations For Preclinical Epilepsy Drug DiscoveryThe International League Against Epilepsy Working Group On Recommendations For Preclinical Epilepsy Drug Discovery.
    • (2012) Epilepsia , vol.53 , pp. 571-582
    • Galanopoulou, A.S.1    Buckmaster, P.S.2    Staley, K.J.3
  • 3
    • 66849097996 scopus 로고    scopus 로고
    • Update of the stroke therapy academic industry roundtable preclinical recommendations
    • the STAIR Group
    • Fisher M, Feuerstein G, Howells DW, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009, 40:2244-2250. the STAIR Group.
    • (2009) Stroke , vol.40 , pp. 2244-2250
    • Fisher, M.1    Feuerstein, G.2    Howells, D.W.3
  • 4
    • 84862297965 scopus 로고    scopus 로고
    • Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies
    • Shineman DW, Basi GS, Bizon JL, et al. Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies. Alzheimers Res Ther 2011, 3:28.
    • (2011) Alzheimers Res Ther , vol.3 , pp. 28
    • Shineman, D.W.1    Basi, G.S.2    Bizon, J.L.3
  • 5
    • 84856531446 scopus 로고    scopus 로고
    • Replication and reproducibility in spinal cord injury research
    • Steward O, Popovich PG, Dietrich WD, Kleitman N Replication and reproducibility in spinal cord injury research. Exp Neurol 2012, 233:597-605.
    • (2012) Exp Neurol , vol.233 , pp. 597-605
    • Steward, O.1    Popovich, P.G.2    Dietrich, W.D.3    Kleitman, N.4
  • 6
    • 77649285022 scopus 로고    scopus 로고
    • Guidelines for preclinical animal research in ALS/MND: A consensus meeting
    • Ludolph AC, Bendotti C, Blaugrund E, et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler 2010, 11:38-45.
    • (2010) Amyotroph Lateral Scler , vol.11 , pp. 38-45
    • Ludolph, A.C.1    Bendotti, C.2    Blaugrund, E.3
  • 7
    • 84888201969 scopus 로고    scopus 로고
    • Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy
    • Brooks-Kayal AR, Bath KG, Berg AT, et al. Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy. Epilepsia 2013, 54(suppl 4):44-60.
    • (2013) Epilepsia , vol.54 , Issue.SUPPL. 4 , pp. 44-60
    • Brooks-Kayal, A.R.1    Bath, K.G.2    Berg, A.T.3
  • 8
    • 84891679696 scopus 로고    scopus 로고
    • Epilepsy therapy development: technical and methodologic issues in studies with animal models
    • Galanopoulou AS, Kokaia M, Loeb JA, et al. Epilepsy therapy development: technical and methodologic issues in studies with animal models. Epilepsia 2013, 54(suppl 4):13-23.
    • (2013) Epilepsia , vol.54 , Issue.SUPPL. 4 , pp. 13-23
    • Galanopoulou, A.S.1    Kokaia, M.2    Loeb, J.A.3
  • 9
    • 77953781386 scopus 로고    scopus 로고
    • A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible
    • Hooijmans CR, Leenaars M, Ritskes-Hoitinga M A gold standard publication checklist to improve the quality of animal studies, to fully integrate the Three Rs, and to make systematic reviews more feasible. Altern Lab Anim 2010, 38:167-182.
    • (2010) Altern Lab Anim , vol.38 , pp. 167-182
    • Hooijmans, C.R.1    Leenaars, M.2    Ritskes-Hoitinga, M.3
  • 10
    • 84872759925 scopus 로고    scopus 로고
    • Successfully Climbing the "STAIRs": Surmounting Failed Translation of Experimental Ischemic Stroke Treatments
    • Kahle MP, Bix GJ Successfully Climbing the "STAIRs": Surmounting Failed Translation of Experimental Ischemic Stroke Treatments. Stroke Res Treat 2012, 2012:374098.
    • (2012) Stroke Res Treat , vol.2012 , pp. 374098
    • Kahle, M.P.1    Bix, G.J.2
  • 11
    • 85041813459 scopus 로고    scopus 로고
    • Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research
    • Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010, 8:e1000412.
    • (2010) PLoS Biol , vol.8
    • Kilkenny, C.1    Browne, W.J.2    Cuthill, I.C.3    Emerson, M.4    Altman, D.G.5
  • 12
    • 84867302438 scopus 로고    scopus 로고
    • A call for transparent reporting to optimize the predictive value of preclinical research
    • Landis SC, Amara SG, Asadullah K, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012, 490:187-191.
    • (2012) Nature , vol.490 , pp. 187-191
    • Landis, S.C.1    Amara, S.G.2    Asadullah, K.3
  • 13
    • 84871840994 scopus 로고    scopus 로고
    • Making methods clearer
    • Editorial
    • Making methods clearer. Nat Neurosci 2013, 16:1. Editorial.
    • (2013) Nat Neurosci , vol.16 , pp. 1
  • 15
    • 84869088933 scopus 로고    scopus 로고
    • Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design
    • Simonato M, Löscher W, Cole AJ, et al. Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia 2012, 53:1860-1867.
    • (2012) Epilepsia , vol.53 , pp. 1860-1867
    • Simonato, M.1    Löscher, W.2    Cole, A.J.3
  • 18
    • 16344387731 scopus 로고    scopus 로고
    • Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)
    • Fisher RS, van Emde Boas W, Blume W, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 2005, 46:470-472.
    • (2005) Epilepsia , vol.46 , pp. 470-472
    • Fisher, R.S.1    van Emde Boas, W.2    Blume, W.3
  • 19
    • 84899493269 scopus 로고    scopus 로고
    • A practical clinical definition of epilepsy
    • Fisher RS, Acevedo C, Arzimanoglou A, et al. A practical clinical definition of epilepsy. Epilepsia 2014, 55:475-482.
    • (2014) Epilepsia , vol.55 , pp. 475-482
    • Fisher, R.S.1    Acevedo, C.2    Arzimanoglou, A.3
  • 20
    • 84891698175 scopus 로고    scopus 로고
    • Issues related to development of antiepileptogenic therapies
    • Pitkänen A, Nehlig A, Brooks-Kayal AR, et al. Issues related to development of antiepileptogenic therapies. Epilepsia 2013, 54(suppl 4):35-43.
    • (2013) Epilepsia , vol.54 , Issue.SUPPL. 4 , pp. 35-43
    • Pitkänen, A.1    Nehlig, A.2    Brooks-Kayal, A.R.3
  • 21
    • 77954625557 scopus 로고    scopus 로고
    • Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies
    • Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51:1069-1077.
    • (2010) Epilepsia , vol.51 , pp. 1069-1077
    • Kwan, P.1    Arzimanoglou, A.2    Berg, A.T.3
  • 22
    • 84891676185 scopus 로고    scopus 로고
    • Issues related to development of new antiseizure treatments
    • Wilcox KS, Dixon-Salazar T, Sills GJ, et al. Issues related to development of new antiseizure treatments. Epilepsia 2013, 54(suppl 4):24-34.
    • (2013) Epilepsia , vol.54 , Issue.SUPPL. 4 , pp. 24-34
    • Wilcox, K.S.1    Dixon-Salazar, T.2    Sills, G.J.3
  • 23
    • 84888381473 scopus 로고    scopus 로고
    • Epilepsy biomarkers
    • Engel J, Pitkänen A, Loeb JA, et al. Epilepsy biomarkers. Epilepsia 2013, 54(suppl 4):61-69.
    • (2013) Epilepsia , vol.54 , Issue.SUPPL. 4 , pp. 61-69
    • Engel, J.1    Pitkänen, A.2    Loeb, J.A.3
  • 24
    • 23244451582 scopus 로고    scopus 로고
    • Biomarkers and surrogate markers: an FDA perspective
    • Katz R Biomarkers and surrogate markers: an FDA perspective. NeuroRx 2004, 1:189-195.
    • (2004) NeuroRx , vol.1 , pp. 189-195
    • Katz, R.1
  • 26
    • 84891673132 scopus 로고    scopus 로고
    • Development of new treatment approaches for epilepsy: unmet needs and opportunities
    • French JA, White HS, Klitgaard H, et al. Development of new treatment approaches for epilepsy: unmet needs and opportunities. Epilepsia 2013, 54(suppl 4):3-12.
    • (2013) Epilepsia , vol.54 , Issue.SUPPL. 4 , pp. 3-12
    • French, J.A.1    White, H.S.2    Klitgaard, H.3
  • 27
    • 42949140259 scopus 로고    scopus 로고
    • Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex
    • Zeng LH, Xu L, Gutmann DH, Wong M Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008, 63:444-453.
    • (2008) Ann Neurol , vol.63 , pp. 444-453
    • Zeng, L.H.1    Xu, L.2    Gutmann, D.H.3    Wong, M.4
  • 28
    • 84890806945 scopus 로고    scopus 로고
    • Everolimus treatment of refractory epilepsy in tuberous sclerosis complex
    • Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013, 74:679-687.
    • (2013) Ann Neurol , vol.74 , pp. 679-687
    • Krueger, D.A.1    Wilfong, A.A.2    Holland-Bouley, K.3
  • 29
    • 70350787254 scopus 로고    scopus 로고
    • Epileptogenesis in the immature brain: emerging mechanisms
    • Rakhade SN, Jensen FE Epileptogenesis in the immature brain: emerging mechanisms. Nat Rev Neurol 2009, 5:380-391.
    • (2009) Nat Rev Neurol , vol.5 , pp. 380-391
    • Rakhade, S.N.1    Jensen, F.E.2
  • 31
    • 78751488401 scopus 로고    scopus 로고
    • Mechanisms of epileptogenesis and potential treatment targets
    • Pitkänen A, Lukasiuk K Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011, 10:173-186.
    • (2011) Lancet Neurol , vol.10 , pp. 173-186
    • Pitkänen, A.1    Lukasiuk, K.2
  • 32
    • 39749159858 scopus 로고    scopus 로고
    • Early treatment suppresses the development of spike-wave epilepsy in a rat model
    • Blumenfeld H, Klein JP, Schridde U, et al. Early treatment suppresses the development of spike-wave epilepsy in a rat model. Epilepsia 2008, 49:400-409.
    • (2008) Epilepsia , vol.49 , pp. 400-409
    • Blumenfeld, H.1    Klein, J.P.2    Schridde, U.3
  • 33
    • 84875859244 scopus 로고    scopus 로고
    • Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy
    • Dezsi G, Ozturk E, Stanic D, et al. Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy. Epilepsia 2013, 54:635-643.
    • (2013) Epilepsia , vol.54 , pp. 635-643
    • Dezsi, G.1    Ozturk, E.2    Stanic, D.3
  • 34
    • 84877927616 scopus 로고    scopus 로고
    • Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study
    • Cook MJ, O'Brien TJ, Berkovic SF, et al. Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study. Lancet Neurol 2013, 12:563-571.
    • (2013) Lancet Neurol , vol.12 , pp. 563-571
    • Cook, M.J.1    O'Brien, T.J.2    Berkovic, S.F.3
  • 35
    • 85027950708 scopus 로고    scopus 로고
    • Seizure diaries for clinical research and practice: limitations and future prospects
    • Fisher RS, Blum DE, DiVentura B, et al. Seizure diaries for clinical research and practice: limitations and future prospects. Epilepsy Behav 2012, 24:304-310.
    • (2012) Epilepsy Behav , vol.24 , pp. 304-310
    • Fisher, R.S.1    Blum, D.E.2    DiVentura, B.3
  • 36
    • 80054825753 scopus 로고    scopus 로고
    • Biomarkers in epilepsy: introduction
    • Engel J Biomarkers in epilepsy: introduction. Biomarkers Med 2011, 5:537-544.
    • (2011) Biomarkers Med , vol.5 , pp. 537-544
    • Engel, J.1
  • 37
    • 84865355051 scopus 로고    scopus 로고
    • High-frequency oscillations - where we are and where we need to go
    • Engel J, da Silva FL High-frequency oscillations - where we are and where we need to go. Prog Neurobiol 2012, 98:316-318.
    • (2012) Prog Neurobiol , vol.98 , pp. 316-318
    • Engel, J.1    da Silva, F.L.2
  • 38
    • 80054828173 scopus 로고    scopus 로고
    • High-frequency oscillations and other electrophysiological biomarkers of epilepsy: clinical studies
    • Worrell G, Gotman J High-frequency oscillations and other electrophysiological biomarkers of epilepsy: clinical studies. Biomarkers Med 2011, 5:557-566.
    • (2011) Biomarkers Med , vol.5 , pp. 557-566
    • Worrell, G.1    Gotman, J.2
  • 39
    • 80054807184 scopus 로고    scopus 로고
    • Prospects for imaging-related biomarkers of human epileptogenesis: a critical review
    • Gomes WA, Shinnar S Prospects for imaging-related biomarkers of human epileptogenesis: a critical review. Biomarkers Med 2011, 5:599-606.
    • (2011) Biomarkers Med , vol.5 , pp. 599-606
    • Gomes, W.A.1    Shinnar, S.2
  • 40
    • 80054811727 scopus 로고    scopus 로고
    • 11C]-methyl-L-tryptophan PET for tracer localization of epileptogenic brain regions: clinical studies
    • 11C]-methyl-L-tryptophan PET for tracer localization of epileptogenic brain regions: clinical studies. Biomarkers Med 2011, 5:577-584.
    • (2011) Biomarkers Med , vol.5 , pp. 577-584
    • Kumar, A.1    Asano, E.2    Chugani, H.T.3
  • 41
    • 80054806792 scopus 로고    scopus 로고
    • Molecular biomarkers of epileptogenesis
    • Pitkänen A, Lukasiuk K Molecular biomarkers of epileptogenesis. Biomarkers Med 2011, 5:629-633.
    • (2011) Biomarkers Med , vol.5 , pp. 629-633
    • Pitkänen, A.1    Lukasiuk, K.2
  • 42
    • 80054797400 scopus 로고    scopus 로고
    • Brain inflammation as a biomarker in epilepsy
    • Vezzani A, Friedman A Brain inflammation as a biomarker in epilepsy. Biomarkers Med 2011, 5:607-614.
    • (2011) Biomarkers Med , vol.5 , pp. 607-614
    • Vezzani, A.1    Friedman, A.2
  • 43
    • 84891714244 scopus 로고    scopus 로고
    • Proposal for a "phase II" multicenter trial model for preclinical new antiepilepsy therapy development
    • O'Brien TJ, Ben-Menachem E, Bertram EH, et al. Proposal for a "phase II" multicenter trial model for preclinical new antiepilepsy therapy development. Epilepsia 2013, 54(suppl 4):70-74.
    • (2013) Epilepsia , vol.54 , Issue.SUPPL. 4 , pp. 70-74
    • O'Brien, T.J.1    Ben-Menachem, E.2    Bertram, E.H.3
  • 44
    • 80052248654 scopus 로고    scopus 로고
    • Reliability of 'new drug target' claims called into question
    • Mullard A Reliability of 'new drug target' claims called into question. Nat Rev Drug Discov 2011, 10:643-644.
    • (2011) Nat Rev Drug Discov , vol.10 , pp. 643-644
    • Mullard, A.1
  • 45
    • 80055088241 scopus 로고    scopus 로고
    • Believe it or not: how much can we rely on published data on potential drug targets?
    • Prinz F, Schlange T, Asadullah K Believe it or not: how much can we rely on published data on potential drug targets?. Nat Rev Drug Discov 2011, 10:712.
    • (2011) Nat Rev Drug Discov , vol.10 , pp. 712
    • Prinz, F.1    Schlange, T.2    Asadullah, K.3
  • 46
    • 84861998609 scopus 로고    scopus 로고
    • Should preclinical studies be registered?
    • Kimmelman J, Anderson JA Should preclinical studies be registered?. Nat Biotechnol 2012, 30:488-489.
    • (2012) Nat Biotechnol , vol.30 , pp. 488-489
    • Kimmelman, J.1    Anderson, J.A.2
  • 47
    • 84876665206 scopus 로고    scopus 로고
    • Power failure: why small sample size undermines the reliability of neuroscience
    • Button KS, Ioannidis JP, Mokrysz C, et al. Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 2013, 14:365-376.
    • (2013) Nat Rev Neurosci , vol.14 , pp. 365-376
    • Button, K.S.1    Ioannidis, J.P.2    Mokrysz, C.3
  • 49
    • 79952756154 scopus 로고    scopus 로고
    • Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism
    • Baillie TA, Rettie AE Role of biotransformation in drug-induced toxicity: influence of intra- and inter-species differences in drug metabolism. Drug Metab Pharmacokinet 2011, 26:15-29.
    • (2011) Drug Metab Pharmacokinet , vol.26 , pp. 15-29
    • Baillie, T.A.1    Rettie, A.E.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.